News | April 21, 2021
PM urges vaccine manufacturers to scale production capacity
The country has constantly worked with the spirit of public-private partnership
The country has constantly worked with the spirit of public-private partnership
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
India produces 60% of the world’s vaccine
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The vaccine was 85 percent effective in preventing severe disease across all regions.
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
CEO Stéphane Bancel framed the changes as essential to scaling the business
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Subscribe To Our Newsletter & Stay Updated
